| Literature DB >> 21774594 |
W Elaine Hardman1, Gabriela Ion, Juliana A Akinsete, Theodore R Witte.
Abstract
Walnuts contain multiple ingredients that, individually, have been shown to slow cancer growth, including omega-3 fatty acids, antioxidants, and phytosterols. In previous research, consumption of walnuts has slowed the growth of implanted breast cancers. We wanted to determine whether regular walnut consumption might reduce the risk for developing cancer. Homozygous male C(3)1 TAg mice were bred with female SV129 mice consuming either the control AIN-76 diet or the walnut-containing diet. At weaning, the female hemizygous pups were randomized to control or walnut-containing diets and followed for tumor development. Compared to a diet without walnuts, consumption of walnuts significantly reduced tumor incidence (fraction of mice with at least one tumor), multiplicity (number of glands with tumor/mouse), and size. Gene expression analyses indicated that consumption of the walnut diet altered expression of multiple genes associated with proliferation and differentiation of mammary epithelial cells. A comparison with another dietary intervention indicated that the omega 3 content alone did not account for the extent of tumor suppression due to the walnut. The results of this study indicate that walnut consumption could contribute to a healthy diet to reduce risk for breast cancer.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21774594 PMCID: PMC3474134 DOI: 10.1080/01635581.2011.589959
Source DB: PubMed Journal: Nutr Cancer ISSN: 0163-5581 Impact factor: 2.900
Compositions of the diets
| Both Diets | Walnut Diet (18% of calories from walnut) | |||||
|---|---|---|---|---|---|---|
| Diet Compositions | Corn Oil (Control) Diet g/kg diet | Calories/g diet | % of total energy | g/kg diet | Additional nutrient contained in 111 g walnut/kg diet | |
| Casein | 200 | 0.80 | 19.2 | 183 g | Protein: 17.2 g | |
| Sucrose | 450 | 1.800 | 43.4 | 450 g | ||
| Corn starch | 150 | 0.60 | 14.46 | 135 g | Carbohydrate: 15.5 g | |
| Alphacel | 50 | 0 | 0 | 48 g | Fiber: 2.0 g | |
| Choline bitartrate | 2.0 | 0 | 0 | 2g | ||
| DL-methionine | 3.0 | 0 | 0 | 3g | ||
| AIN-76 Mineral mix | 35.0 | 0.02 | 0.4 | 35 g | ||
| AIN-76A Vitamin mix | 10.0 | 0.030 | 0.7 | 10 g | ||
| Ground walnut | 0 | 111 g | ||||
| Fat (10% total fat) | 100 g corn oil | 0.90 | 21.7 | 26.3 g corn oil | Fat: 73.7 g | |
| Totals | 1,000 g | 4.15 cal/g | 99.9 | 1,003g | (4.6 g water in walnut) | |
| Fat in diet | From corn oil g/kg diet | From corn oil g/kg diet | From walnut g/kg diet | Total g/kg diet | ||
| Oleic acid | 27.33 | 7.2 | 9.7 | 16.9 | ||
| Linoleic acid | 53.2 | 14.0 | 41.9 | 55.9 | ||
| 1.2 | 0.3 | 10.0 | 10.3 | |||
| Total saturated fat | 12.9 | 3.3 | 6.7 | 10.0 | ||
Fat composition (g/100 g) of corn oil and walnut from Ref. 15. Small amounts of various lipids make up the remainder of the fat and are not listed. Shown are the compositions of the corn oil and walnut-containing diets of this article. The canola oil diet, referred to in Fig. 4, had 10% canola oil instead of 10% corn oil and is detailed in Ref. 21.
Genes with significantly different expressions as determined by PCR array
| Symbol | Fold Difference | Fold Difference | Fold Difference | |||
|---|---|---|---|---|---|---|
| Activating transcription factor 2 (ATF2) | 0.004 | 2.597 | 0.034 | 1.737 | 0.021 | 1.838 |
| Bcl2-associated X protein (BAX) | 0.079 | 107.535 | 0.074 | 119.263 | 0.079 | 105.420 |
| B-cell leukemia/lymphoma 2 (Bcl2) | 0.163 | 27.338 | 0.292 | 11.867 | 0.178 | 24.098 |
| Baculoviral IAP repeat-containing 2 | 0.002 | 4.328 | 0.076 | 1.896 | 0.007 | 3.375 |
| (Birc2) | ||||||
| Bone morphogenetic protein 2 (BMP2) | 0.109 | 17.182 | 0.095 | 19.865 | 0.139 | 12.914 |
| Bone morphogenetic protein 4 (BMP4) | 0.486 | 3.254 | 0.450 | 3.592 | 0.399 | 4.228 |
| Cyclin-dependent kinase inhibitor 2A | 0.011 | 950.691 | 0.026 | 216.092 | 0.024 | 308.865 |
| [Cdkn2a (p16)] | ||||||
| CCAAT/enhancer binding protein | 0.014 | 2876.968 | 0.027 | 790.342 | 0.016 | 2152.305 |
| (C/EBP), beta | ||||||
| Chemokine (C-X-C motif) ligand 1 | 0.001 | 9.309 | 0.001 | 4.728 | 0.000 | 3.732 |
| (Cxcl1) | ||||||
| Early growth response 1 (EGR1) | 0.033 | 472.608 | 0.037 | 363.002 | 0.057 | 168.410 |
| Engrailed 1 (En1) | 0.000 | 21.449 | 0.162 | 6.895 | 0.000 | 43.236 |
| Fas (TNF receptor superfamily member) | 0.000 | 5.794 | 0.123 | 1.782 | 0.000 | 5.084 |
| Fatty acid synthase (Fasn) | 0.365 | 7.350 | 0.447 | 5.280 | 0.332 | 8.649 |
| FBJ osteosarcoma oncogene (FOS) | 0.068 | 67.275 | 0.077 | 59.356 | 0.124 | 29.446 |
| Growth arrest and | 0.067 | 3.519 | 0.083 | 3.156 | 0.166 | 2.362 |
| DNA-damage-inducible 45 alpha (Gadd45a) | ||||||
| Gene regulated by estrogen in breast | 0.280 | −2.328 | 0.096 | −4.923 | 0.150 | −4.134 |
| cancer protein (Grebl) | ||||||
| Glycogen synthase 1, muscle (Gys1) | 0.002 | −2.717 | 0.009 | −2.213 | 0.000 | −2.086 |
| Hedgehog-interacting protein (Hhip) | 0.035 | 2.111 | 0.164 | −3.308 | 0.003 | 4.285 |
| Hexokinase 2 (Hk2) | 0.192 | 35.886 | 0.237 | 24.499 | 0.213 | 29.719 |
| Heat shock factor 1 (Hsf1) | 0.200 | 15.378 | 0.987 | −1.034 | 0.221 | 13.462 |
| Insulin-like growth factor binding | 0.241 | 18.214 | 0.205 | 24.584 | 0.229 | 19.904 |
| protein 4 (Igfbp4) | ||||||
| Inhibitor of kappaB kinase beta (Ikbkb) | 0.305 | −2.727 | 0.168 | −6.874 | 0.236 | −3.456 |
| Interleukin 2 (Il2) | 0.182 | 2.749 | 0.127 | 4.986 | 0.804 | 1.260 |
| Interleukin 2 receptor, alpha chain | 0.091 | −4.650 | 0.042 | −12.622 | 0.103 | −5.448 |
| (Il2ra) | ||||||
| Interleukin 4 receptor, alpha (Il4ra) | 0.025 | −6.221 | 0.045 | −8.601 | 0.029 | −6.317 |
| Jun oncogene (Jun) | 0.000 | 506.529 | 0.336 | 2.230 | 0.000 | 465.456 |
| Transformed mouse 3T3 cell double | 0.015 | 71.937 | 0.036 | 29.135 | 0.020 | 53.199 |
| minute 2 (Mdm2) | ||||||
| Matrix metallopeptidase 10 (Mmp10) | 0.077 | 2.350 | 0.167 | 3.487 | 0.541 | 1.275 |
| Matrix metallopeptidase 7 (Mmp7) | 0.206 | 2.285 | 0.004 | 10.664 | 3.647 | |
| Myelocytomatosis oncogene (Myc) | 0.040 | 1.739 | 0.089 | −4.569 | 1.360 | |
| Ngfi-A binding protein 2 (Nab2) | 0.000 | −7.938 | 0.215 | −2.961 | −8.042 | |
| Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha (Nfkbia) | 0.196 | 20.971 | 0.267 | 12.874 | 18.358 | |
| Nitric oxide synthase 2, inducible, macrophage (Nos2) | 0.021 | −3.080 | 0.015 | −2.922 | −1.813 | |
| Patched homolog 1 (Ptch1) | 0.062 | −4.102 | 0.004 | −21.412 | −3.651 | |
| TRAF family member-associated Nf-kappa B activator (Tank) | 0.018 | 4.188 | 0.351 | −2.890 | 3.389 | |
| Transcription factor 7, T-cell specific (Tcf7) | 0.126 | 70.661 | 0.337 | 12.807 | 28.003 | |
| Telomerase reverse transcriptase (Tert) | 0.120 | −1.423 | 0.929 | −1.042 | −1.422 | |
| Tmepai | 0.076 | −5.109 | 0.029 | −147.067 | −8.545 | |
| Tumor necrosis factor (Tnf) | 0.847 | −1.106 | 0.075 | −3.123 | −1.762 | |
| Vascular cell adhesion molecule 1 (Vcam1) | 0.046 | 1.750 | 0.040 | −2.019 | 1.193 | |
| Vascular endothelial growth factor A (Vegfa) | 0.008 | −2.094 | 0.086 | −1.621 | −2.612 | |
| WNT1 inducible signaling pathway protein 1 (Wisp1) | 0.076 | 12.556 | 0.250 | 4.055 | 8.825 |
All comparisons are to the corn oil/corn oil group. Genes with expression that differed by more than twofold or with a P < 0.05 are listed.
The data indicate that walnut consumption influences pathways involved in cell proliferation, cell death, and differentiation of the mammary glands and that would be expected to alter carcinogenesis.
Pathways associated with genes above. Italics denote genes with altered message in above table:
Mitogenic Pathway: Egrl (egr-1), Fos (c-fos), Jun (c-jun), Nab2.
Wnt Pathway: Birc5, Ccnd1 (cyclin D1), Cdh1, Fgf4, Jun (c-jun), Lef1, Myc (c-myc), Pparg, Tcf7, Vegfa, Wisp1.
Hedgehog Pathway: Bmp2, Bmp4, En1 (engrailed), Foxa2 (forkhead box A2/HNF3B), Hhip, Ptch1 (patched 1), Wnt1, Wnt2.
TGF-β Pathway: Cdkn 1a (p21Waf1, p2lCip1), Cdkn 1b (p27), Cdkn2a (p16, Cdkn2b (p15 Ink2b).
Survival Pathway: PI3 Kinase/AKT Pathway: Bcl2 (Bcl-2), Ccnd1, Fn1 (fibronectin), Jun (c-jun), Mmp7 (matrilysin), Myc (c-myc).
Jak/Src Pathway: Bcl2 (Bcl-2), Bcl2ll (Bc1-XL).
p53 Pathway: Bax, Cdkn1a (p2lWafl, p2lCipl), Ei24 (Pig3), Fas (Tnfrsf6), Gadd45a (gadd45), Igfbp3, Mdm2.
Stress Pathway: Atf2, Fos (c-fos), Hsf1 (tcf5), Hspb1 (Hsp25), Myc (c-myc), Trp53 (p53).
NFκB Pathway: Birc1a, Birc2 (c-IAP2), Birc3 (c-IAP1), Ccl20, Cxcl1, Icam1, Ikbkb, I11a, Il2, Lta (TNFb), Nfkbia, Nos2 (iNOS), Tank, Tnf (TNFa), Tert, Vcam1.
NFAT Pathway: Cd5, Fasl (Tnfsf6), Il2.
CREB Pathway: Cypl9al, Egr1 (egr-1), Fos (c-fos).
Jak-Stat Pathway: Cxcl9 (MIG), Il4ra, Irf1, Mmp10 (stromelysin-2), Nos2 (iNOS).
Estrogen Pathway: Bcl2 (Bcl-2), Brcal, Greb1, Igfbp4, Nrip1.
Androgen Pathway: Cdk2, Cdkn1a (p21Waf1, p21Cip1), Tmepai.
Calcium and Protein Kinase C Pathway: Csf2 (GM-CSF), Fos (c-fos), Il2, Il2ra (IL-2 R?), Jun (c-jun), Myc (c-myc), Odc1, Tfrc.
Phospholipase C Pathway: Bcl2 (Bcl-2), Egr1, Fos (c-fos), Icam1, Jun (c-jun), Nos2 (iNOS), Ptgs2 (cox-2), Vcaml.
Insulin Pathway: Cebpb (C/EBP-β), Fasn (fatty acid synthase), Gys1 (GS, glycogen synthase), Hk2 (hexokinase II), Lep (Ob).
LDL Pathway: Ccl2, Csf2 (GM-CSF), Sele, Selp (P-selectin), Vcaml.
Retinoic Acid Pathway: En1 (engrailed), Hoxa1, Rbp1 (CRBPI).
Available statistical software only allowed t-tests of test group vs. a control group.